Method and system for treating cancer cachexia
First Claim
1. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine, wherein the cancer is bladder cancer;
- andwherein the bacillus calmette-guerin has been modified via a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system to produce tomatidine.
2 Assignments
0 Petitions
Accused Products
Abstract
Various embodiments of the present invention are directed to the field of Oncology, and in particular embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual'"'"'s microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, p53 protein, statins, etc., is employed to address cancerous conditions. In several embodiments, the administration of such beneficial bacteria and microbes to an individual'"'"'s microbiome invokes either an active (or a passive) immune response to destroy, weaken or render less invasive certain cancerous cells, and preferably maintains muscle tissue to combat cancer cachexia.
-
Citations
7 Claims
-
1. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine, wherein the cancer is bladder cancer;
- and
wherein the bacillus calmette-guerin has been modified via a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system to produce tomatidine.
- and
-
2. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine, wherein the cancer is bladder cancer;
- and
wherein the bacillus calmette-guerin is further adapted to produce rapamycin.
- and
-
3. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine, wherein the cancer is bladder cancer;
- and
wherein the bacillus calmette-guerin is further adapted to produce p53.
- and
-
4. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine, wherein the cancer is colorectal cancer;
- and
wherein the bacillus calmette-guerin is further adapted to produce rapamycin.
- and
-
5. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine, wherein the cancer is colorectal cancer;
- and
wherein the bacillus calmette-guerin is further adapted to produce p53.
- and
-
6. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a microbial composition comprising bacillus calmette-guerin adapted to produce p53 and rapamycin;
- and
wherein the composition has been modified to express tomatidine.
- and
-
7. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a microbial composition comprising bacillus calmette-guerin adapted to produce p53 and rapamycin;
- and
wherein the composition further comprises phosphatase and tensin homolog (PTEN).
- and
Specification